Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Status:
Terminated
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, open label, multi-center study of CMB305 (sequentially administered LV305
[a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene] and G305 [NY-ESO-1
recombinant protein plus GLA-SE]) in patients with melanoma, sarcoma, ovarian cancer, or
non-small cell lung cancer that express NY-ESO-1.